Business Context and Reporting Period
Company: TECHNE Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2000
Business Overview: TECHNE is a holding company with two primary operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in the U.S. and R&D Systems Europe Ltd. The company operates in two main segments: Hematology Controls (blood analysis instruments for clinical labs) and Biotechnology Products (cytokines, antibodies, and assay kits for research and clinical diagnostics). The company is the world's leading supplier of cytokine-related products to the research community.
Key Financial Metrics
| Metric | Fiscal 2000 | Fiscal 1999 | Fiscal 1998 |
|---|---|---|---|
| Net Sales | $103,838,155 | $90,900,697 | $67,291,438 |
| Gross Margin | 74.2% | 69.9% | 70.3% |
| Net Earnings | $26,582,797 | $16,656,010 | $15,182,961 |
| Diluted EPS | $1.26 | $0.81 | $0.77 |
| Operating Cash Flow | $38,739,403 | $28,421,859 | $20,875,469 |
| Total Assets | $180,409,581 | $123,800,519 | $72,785,000 (approx) |
| Long-Term Debt | $18,935,049 | $0 | $0 |
| Cash & Equivalents | $17,356,108 | $12,769,468 | $26,113,607 |
| Short-Term Investments | $42,468,183 | $16,344,656 | $15,321,935 (approx) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14% to $103.8 million, driven primarily by a 17% increase in Biotechnology Division sales ($64.2 million) and a 12% increase in R&D Europe sales.
- Profitability: Net earnings rose 59% to $26.6 million. Gross margin improved to 74.2% from 69.9%, attributed to higher margins in the Biotechnology Division and the resolution of inventory costs associated with the prior year's Genzyme acquisition.
- Capital Expenditures: Capital expenditures surged to $30.4 million (from $5.6 million in 1999), primarily due to the purchase of the company's Minneapolis facilities for approximately $28 million in July 1999.
- Debt Structure: The company incurred $19.8 million in long-term debt (mortgage) to finance the facility acquisition, a significant change from having no long-term debt in the prior year.
- Investment Portfolio: Total cash, cash equivalents, and short-term investments increased 105% to $59.8 million, reflecting strong operating cash flow.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects to meet future cash requirements through available funds and operating cash flow. Capital additions for fiscal 2001 are projected at approximately $5.8 million.
- Legal Contingency (Amgen): Amgen Inc. has presented invoices totaling $31.9 million for materials allegedly provided under a contract with no accounting for nine years. TECHNE has filed a declaratory judgment action seeking a court declaration that no amount is owed. Management believes no material amount is owed and that the resolution will not have a material adverse effect.
- Investment in ChemoCentryx: The company holds a 49% interest in ChemoCentryx, Inc. (CCX). While CCX reported losses in prior years, research grant money received in fiscal 2000 offset these expenses, reducing the negative impact on TECHNE's earnings.
- Risks: Key risks include technological obsolescence in the biotechnology and hematology industries, intense competition, potential patent infringement claims, and the ability to attract and retain key scientific personnel.
- Regulatory: Hematology controls and specific diagnostic kits are subject to FDA regulation. Research products generally do not require FDA clearance.
Investor Verification Checklist
- Amgen Litigation: Verify the status of the $31.9 million dispute with Amgen Inc. and any potential financial exposure.
- Debt Servicing: Confirm the impact of the new $19.8 million mortgage on future cash flows and interest expense (fixed at 7% for the first seven years).
- ChemoCentryx Performance: Monitor the financial performance of the 49% equity investment in ChemoCentryx, Inc., as its losses are consolidated into TECHNE's results.
- Revenue Concentration: Confirm that no single customer accounts for more than 10% of revenue (as stated in the filing).
- Real Estate Options: Review the status of the two real estate options adjacent to the Minneapolis facility, including the $2 million deposits and potential future capital requirements.